According to a May 4 Reuters survey that included 16 analysts covering XRAY, the stock is a “buy” or “strong buy” as per 62.5% of analysts (or ten), while 31.3% (or five) of these analysts have “hold” recommendations on XRAY stock. The remaining analyst has provided a “sell” recommendation on Dentsply Sirona.
According to the same survey, analysts’ consensus 12-month target price for XRAY is $67.86. This target reflects a potential investment return of ~37.8% from XRAY stock over the next 12 months. XRAY closed at $49.24 on May 3. The stock had a 12-month consensus target price of $68.36 a month earlier on April 9.
In comparison, Dentsply Sirona’s peers Danaher (DHR), Zimmer Biomet Holdings (ZBH), and Align Technology (ALGN) have average analyst target prices of $111.44, $132.65, and $297.77, respectively. These target prices represent potential returns of 12.6%, 15.2%, and 16.7%, respectively, over the next 12 months.
Recent recommendation revisions and updates
On April 16, Jefferies cut its target price on Dentsply Sirona from $70 to $66 per share while reiterating its “buy” rating on the stock. On March 28, Barclays also cut its price target on Dentsply Sirona from $62 to $60. Further, on March 27, Barrington Research reduced its price target on XRAY stock from $70 to $69. Notably, Barrington Research also decreased its target price on XRAY stock from $73 to $70 on March 5 following the release of the company’s 4Q17 results on March 2.
For more discussion on the rationale behind Barrington’s price cut, read Why Barrington Research Cut Its Target Price on Dentsply Sirona. On the same day, H.C. Wainwright and Stifel also cut their target prices on Dentsply Sirona.
In the next article, we’ll take a look at Dentsply Sirona’s 1Q18 earnings expectations.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!